Dr. Smiths Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
as on 16-11-2024
- Paid Up Capital ₹ 2.20 Cr
as on 16-11-2024
- Company Age 9 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 16.87 Cr
as on 16-11-2024
- Revenue 39.80%
(FY 2023)
- Profit 129.24%
(FY 2023)
- Ebitda 678.07%
(FY 2023)
- Net Worth 35.44%
(FY 2023)
- Total Assets -35.07%
(FY 2023)
About Dr. Smiths Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 2.20 Cr.
The company currently has active open charges totaling ₹16.87 Cr.
Suraj Zanwar, Prakashchandra Rathi, and Riyaz Khan serve as directors at the Company.
- CIN/LLPIN
U24246PN2015PTC154818
- Company No.
154818
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Apr 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Dr. Smiths Biotech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suraj Zanwar  | Director | 24-Apr-2015 | Current |
| Prakashchandra Rathi | Director | 11-Sep-2021 | Current |
| Riyaz Khan | Director | 03-Jun-2019 | Current |
Financial Performance of Dr. Smiths Biotech.
Dr. Smiths Biotech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 39.8% increase. The company also saw a substantial improvement in profitability, with a 129.24% increase in profit. The company's net worth Soared by an impressive increase of 35.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dr. Smiths Biotech?
In 2023, Dr. Smiths Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Skybiotech Life Sciences Private LimitedActive 10 years 4 monthsPrakashchandra Rathi is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 18 Feb 2022 | ₹0.71 M | Open |
Sidbi Creation Date: 31 Jan 2017 | ₹2.00 Cr | Open |
Sidbi Creation Date: 31 Jan 2017 | ₹14.80 Cr | Open |
How Many Employees Work at Dr. Smiths Biotech?
Dr. Smiths Biotech has a workforce of 22 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dr. Smiths Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dr. Smiths Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
